Clinical Trial Update: A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis [Phase 3]

View source ↗

Summary

Phase 3 trial of baricitinib in children and adolescents with atopic dermatitis has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Baricitinib (baricitinib)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2023-06-29